15328 Federal Register / Vol. 76, No. 54 / Monday, March 21, 2011 / Notices 

• Tiopronin does not inhibit the 

activity of ABC transporters, thereby 

reducing the chance of undesired sideeffects during treatment 

• The effects of Tiopronin correlates 

with the level of ABC transporter 

expression, allowing healthy cells to 

better survive treatments 

• Tiopronin can also improve the 

effectiveness of chemotherapy by resensitizing resistant cells that were 

previously considered impervious to 

treatment 

• Tiopronin has already been 

approved for use in humans for the 

treatment of cytinuria, facilitating the 

pathway for use in humans as a 

treatment for cancer 

Development Status: Preclinical stage 

of development, in vitro data 

Inventors: Andrew S. Goldsborough et 

al. (NCI) 

US Patent Status: US Provisional 

Application 61/407,948 (E–227–2010/0– 

US–01) 

Licensing Status: The technology is 

available for exclusive licensing. 

Licensing Contact: David Lambertson, 

PhD; 301–435–4632; 

lambertsond@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, 

Multidrug Resistance Section, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact John Hewes, PhD at 301–435– 

3121 or hewesj@mail.nih.gov for more 

information. 

Identification of EGFR as a Receptor for 

AAV6 Transduction 

Description of Technology: AAV 

vectors offer unique advantages in gene 

therapy applications. Studies have 

shown that these replication deficient 

parvovirus vectors can deliver DNA to 

specific tissues and confer long-term 

transgene expression in a variety of 

systems. Although many studies have 

looked at the tissue-specific expression 

elicited by each of the AAV serotypes, 

a true understanding of how AAV 

transduces these tissues is still unclear. 

Of the large AAV family, only a few 

receptors or co-receptors have been 

identified. The ability to better target 

transduction to specific tissues on the 

basis of the receptors that each serotype 

uses for entry is essential for selecting 

a serotype given the receptor expression 

in specific tissue, or to exploit altered 

receptor expression under disease 

conditions. 

AAV6 has been reported to effectively 

transduce muscle, lung, brain, and 

multiple types of tumors, including 

gliomas and lung adenocarcinomas. By 

using a bioinformatics based screen 

approach, the NIH investigators 

discovered that the epidermal growth 

factor receptor (EGFR) is a co-receptor 

for AAV6 infection in mammalian cells, 

and is necessary for efficient vector 

internalization. 

Applications and Market: Improved 

gene therapy applications. 

Development Status: Pre-clinical stage 

of development. 

Inventors: John A. Chiorini, Melodie 

L. Weller, Michael Schmidt (NIDCR) 

Publication: Weller ML, 

Amornphimoltham P, Schmidt M, 

Wilson PA, Gutkind JS, Chiorini JA. 

Epidermal growth factor receptor is a 

co-receptor for adeno-associated virus 

serotype 6. Nat Med. 2010 

Jun;16(6):662–664. [PubMed: 20473307] 

Patent Status: U.S. Utility Patent 

Application No. 12/879,142 filed 10 Sep 

2010 (HHS Reference No. E–194–2010/ 

0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty B. Tong, 

PhD; 301–594–6565; 

tongb@mail.nih.gov. 

Therapeutic Approach to 

Neurodegenerative Disorders Using a 

TFP5-Peptide 

Description of Technology: This 

invention discloses methods for treating 

neurodegenerative diseases by 

administering cyclin dependent kinase 

5 (Cdk5) inhibitory peptides derived 

from P35, the activator of Cdk5. 

Abnormally hyperactive Cdk5 has been 

shown to be associated with a variety of 

neurodegenerative disorders. Disclosed 

in this invention are isolated peptide 

fragments, pharmaceutical compositions 

and methods for use of such for treating 

subjects with a neurodegenerative 

disease, such as Alzheimer’s disease 

(AD), Amyotrophic Lateral Sclerosis 

(ALS) and Parkinson’s disease (PD). An 

inhibitory fragment, TFP5, disclosed in 

this invention, has been shown to 

ameliorate symptoms of AD in disease 

animal models without any evidence of 

toxicity. In particular, TFP5 treatment of 

rat cortical neurons reduced 

hyperactivation of Cdk5 upon neuronal 

stress and insults. Following 

intraperitoneal (ip) injection, TFP5 was 

capable of crossing the BBB and 

localizing within the brain where it was 

found to rescue memory deficits and 

pathology in a double transgenic mouse 

(APP/PS1) AD model. 

Applications: Therapeutic 

developments (AD, PD, ALS) 

Advantages: The products are small 

peptides that pass the blood brain 

barrier. 

Market: Development for AD, PD, and 

ALS. 

Development Status: Pre-clinical; 

some animal data 

Inventors: Harish C. Pant (NINDS) 

Patent Status: U.S. Provisional 

Application No. 61/387,839 filed 29 Sep 

2010 (HHS Reference No. E–144–2010/ 

0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Steven H. 

Standley, PhD; 301–435–4074; 

sstand@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Neurological 

Disorders and Stroke, Neuronal 

Cytoskeletal Protein Regulation Section, 

is seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

topic of invention or related laboratory 

interests. Please contact Heather Gunas, 

J.D., M.P.H., at 301–451–3944 or 

gunash@mail.nih.gov for more 

information. 

Dated: March 15, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–6569 Filed 3–18–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; GISTE, 

the Geospatial Information Systems Tool 

(5558). 

Date: April 18, 2011. 

Time: 1:30 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 76, No. 54 / Monday, March 21, 2011 / Notices 15329 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4238, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Research Works: Enrollment Workflow 

(2219). 

Date: April 28, 2011. 

Time: 9:30 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 4227, MSC 9550, 6001 

Executive Boulevard, Bethesda, MD 20892– 

9550, (301) 435–1439, lf33c@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA’s 

Science Meetings Logistical Support (1144). 

Date: May 3–4, 2011. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Courtyard by Marriott Rockville, 

2500 Research Boulevard, Rockville, MD 

20850. 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 4227, MSC 9550, 6001 

Executive Boulevard, Bethesda, MD 20892– 

9550, (301) 435–1439, lf33c@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Research Support Services for NIDA AIDS 

Research Program (1207). 

Date: May 5, 2011. 

Time: 9:30 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 4227, MSC 9550, 6001 

Executive Boulevard, Bethesda, MD 20892– 

9550, (301) 435–1439, lf33c@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Development & Manufacture of 

Pharmaceutical Products/Addiction 

Treatment (8899). 

Date: May 24, 2011. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Courtyard by Marriott Rockville, 

2500 Research Boulevard, Rockville, MD 

20850. 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 4227, MSC 9550, 6001 

Executive Boulevard, Bethesda, MD 20892– 

9550, (301) 435–1439, lf33c@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: March 15, 2011. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–6584 Filed 3–18–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, R25 

Summer Programs. 

Date: March 30, 2011. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4238, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–402–6626, 

gm145a@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: March 15, 2011. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–6578 Filed 3–18–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, Functional 

Development of the Mammary Gland. 

Date: April 14, 2011. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Rockville, MD 20852 

(Telephone Conference Call). 

Contact Person: Peter Zelazowski, PhD, 

Scientific Review Officer, Division of 

Scientific Review, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, 6100 Executive 

Blvd., Room 5B01, Bethesda, MD 20892, 

301–435–6902, peter.zelazowski@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: March 15, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–6575 Filed 3–18–11; 8:45 am] 

BILLING CODE 4140–01–P 

mstockstill on DSKH9S0YB1PROD with NOTICES